9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-valerate 21-acetate | 82033-25-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-valerate 21-acetate
• 英文别名: [(8S,9R,10S,11S,13S,14S,16R,17R)-17-(2-acetyloxyacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
• CAS: 82033-25-8
• 化学式: C₂₉H₃₉FO₇
• 分子量: 518.623
• InChiKey: QSZKFXMOBKKROF-GQGOTNMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-valerate 21-acetate 以 甲醇 为溶剂， 生成 地塞米松21-戊酸酯
  参考文献：
  名称：

  Process of selective solvolysis

  摘要：

  17.alpha.-单酯和17.alpha.,21-双酯皮质类固醇是众所周知的，如今代表了局部应用最有效的抗炎化合物群，具有最小的全身作用。

  公开号：

  US04343739A1

文献信息

• COMPOSITION FOR EXTERNAL USE
  申请人：ROHTO PHARMACEUTICAL CO., LTD.

  公开号：EP1849481A1

  公开（公告）日：2007-10-31

  An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.

  本发明的目的是提供一种外用组合物，其中维生素 A、维生素 A 衍生物、维生素 C、特定维生素 C 衍生物、黄嘌呤衍生物、泛素酮和/或透明质酸的经皮吸收性得到改善。 外用组合物的制备方法是将(i)磷脂和(ii)单-或寡-乙二醇醚与(iv)至少一种生物活性成分混合在一起，这些生物活性成分选自透明质酸、透明质酸衍生物、维生素 A、维生素 A 衍生物、维生素 C、特定维生素 C 衍生物、黄嘌呤衍生物、泛醌及其盐类组成的组。
• COSMETIC COMPOSITION
  申请人：Rohto Pharmaceutical Co., Ltd.

  公开号：EP3616683A1

  公开（公告）日：2020-03-04

  Provided is a cosmetic composition that maintains high stability and restrains from becoming cloud. This cosmetic composition is prepared by including (A) polyoxyethylene polyoxypropylene glycol, and (B) an amino acid based surfactant having, in a single molecule thereof, two or more hydrophobic groups and two or more hydrophilic groups. Furthermore, provided is a method of giving a cloudiness-restraining effect to a cosmetic composition, including causing the component (A) and the component (B) to coexist with each other in the cosmetic composition.

  本发明提供了一种化妆品组合物，它能保持高稳定性并防止变浊。 这种化妆品组合物的制备方法是：(A) 聚氧乙烯聚氧丙烯二醇；(B) 氨基酸基表面活性剂，在其单个分子中具有两个或两个以上的疏水基团和两个或两个以上的亲水基团。此外，还提供了一种使化妆品组合物具有抑浊效果的方法，包括使组分（A）和组分（B）在化妆品组合物中共存。
• EMULSIFIED GEL COMPOSITION
  申请人：Hisamitsu Pharmaceutical Co., Inc.

  公开号：EP3760231A1

  公开（公告）日：2021-01-06

  The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.

  本发明提供了一种乳化凝胶组合物，该组合物由生理活性物质、水、胶凝剂、抗剥落剂和 HLB 值为 18 至 20 的表面活性剂组成，其中胶凝剂为非离子水溶性聚合物，抗剥落剂为选自蔗糖、山梨糖醇、聚乙二醇、甘油、（甲基）丙烯酸基聚合物化合物和聚氧乙烯氢化蓖麻油组成的组中的一种或多种化合物。
• Emulsified gel composition
  申请人：HISAMITSU PHARMACEUTICAL CO., INC.

  公开号：US11246830B2

  公开（公告）日：2022-02-15

  The present invention provides an emulsified gel composition comprising a physiologically active substance, water, a gelling agent, an anti-peeling agent, and a surfactant having an HLB value of 18 to 20, in which the gelling agent is a nonionic water-soluble polymer, and the anti-peeling agent is one or more compounds selected from the group consisting of sucrose, sorbitol, polyethylene glycol, glycerin, a (meth)acrylic-based polymer compound, and a polyoxyethylene hydrogenated castor oil.

  本发明提供了一种乳化凝胶组合物，该组合物由生理活性物质、水、胶凝剂、抗剥落剂和 HLB 值为 18 至 20 的表面活性剂组成，其中胶凝剂为非离子水溶性聚合物，抗剥落剂为选自蔗糖、山梨糖醇、聚乙二醇、甘油、（甲基）丙烯酸基聚合物化合物和聚氧乙烯氢化蓖麻油组成的组中的一种或多种化合物。
• Composition For External Use
  申请人：Harada Ayako

  公开号：US20080207560A1

  公开（公告）日：2008-08-28

  An object of the present invention is to provide a composition for external use in which the percutaneous absorbability of vitamin A, vitamin A derivative(s), vitamin C, specific vitamin C derivative(s), xanthine derivative(s), ubiquinone(s) and/or hyaluronic acid is improved. The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.